CLARINET
Lanreotide more than halved the risk of progression in gut and pancreatic neuroendocrine tumours.
PFS median not reached vs 18.0 months (HR 0.47); 24-month PFS 65% vs 33%. Basis for lanreotide's antiproliferative label.
Setting
Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo
Phase
Phase 3
Sponsor
Ipsen
Registry
Headline result
PFS HR 0.47.
Reported
2014
Enrolled
204
In plain words
What these results mean for people, not percentages
Progression-free survivalprimarysurrogate endpoint
- Median 18 months with Placebo.
- Lanreotide: not reached.
- "Not reached" means that, when the data were analysed, more than half of that group had not yet had the event, which is good news for that group.
- A median is a midpoint: half the people did better than this and half did worse.
- Put another way, the treated group had about 53 percent lower chance of the event at any given time (hazard ratio 0.47, likely range 0.3 to 0.73).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
204 participants enrolled.
Progression-free survivalprimary
HR 0.47 (0.3–0.73) · p <0.001
Lanreotide
not reached
Placebo
18 mo
not reached
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Lanreotide | 101 | not reached | 0.47 (0.3–0.73) | <0.001 | — |
| Placebo | 103 | 18 months |
Pages like this
not linked directly; found by shared links- TermCarcinoid syndrome and carcinoid heart disease
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
- TrialPROMID
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.
- ProductCabozantinib
Shares Ipsen, Neuroendocrine tumours.
- TargetSomatostatin receptor 2
Shares Somatostatin analogues (octreotide, lanreotide), Neuroendocrine tumours.